1. Byung Woog Kang, Jong Gwang Kim, In Hee Lee, Han Ik Bae, An Na Seo. Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. World J Gastrointest Oncol 2017;9:293-299.
2. Park S, Kang BW, Lee SJ, Yoon S, Chae YS, Kim JG, Lee KH, Koh SA, Song HS, Park KU, Kim JY, Heo MH, Ryoo HM, Cho YY, Jo J, Lee JL, Lee SA.. Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer. Cancer Chemother Pharmacol 2017;80:187-193.
3. Baek DW, Kang BW, Hwang S, Kim JG, Seo AN, Bae HI, Kwon OK, Lee SS, Chung HY, Yu W. Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. Chonnam Med J 2017;53:140-146.
4. Kim JY, DO YR, Song HS, Cho YY, Ryoo HM, Bae SH, Kim JG, Chae YS, Kang BW, Baek JH, Kim MK, Lee KH, Park K. Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer. Anticancer Research 2017;37:1467-1473.
5. Lee IH, Hwang S, Lee SJ, Kang BW, Baek D, Kim HJ, Park SY, Park JS, Choi GS, Kim JC, Cho SH, Kim JG. Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. Anticancer Research 2017;37:1459-1465.
6. Kang BW, Choi Y, Kwon OK, Lee SS, Chung HY, Yu W, Bae HI, Seo AN, Kang H, Lee SK, Jeon SW, Hur K, Kim JG. High level of viral microRNA-BART20-5p expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Oncotarget 2017
7. Lee SJ, Kang BW, Kim JG, Jung JH, Lee J, Kim WW, Park HY, Jeong JH, Jeong JY, Park JY, Park JH, Chae YS. AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer. Oncology 2017;92:153-160.
8. Lee IH, Lee SJ, Kang BW, Chae YS, Baek D, Hwang S, Kim HJ, Park SY, Park JS, Choi GS, Kim JC, Kim JG. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer. Cancer Chemother Pharmacol 2016;78:1263-1267.
9. Kang BW, Jeon HS, Chae YS, Lee SJ, Park JS, Choi GS, Kim JG. Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer. Anticancer Res 2016;36:3353-61.
10. Yoon S, Kang BW, Park SY, Kim HJ, Park JS, Choi GS, Kim JG. Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. J Cancer Res Clin Oncol 2016;142:1775-1780.
11. Kang BW, Kwon OK, Chung HY, Yu W, Kim JG. Taxanes in the Treatment of Advanced Gastric Cancer. Molecules 2016;21:pii:E651
12. Park SY, Choi GS, Park JS, Kim HJ, Yang CS, Kim JG, Kang BW. Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Case-Control Study from a Single Center. Ann Surg Oncol 2016;23:2266-73.
13. Lee MA, Cho EK, Oh SY, Ahn JB, Lee JY, Thomas B, Jung H, Kim JG. Clinical Practices and Outcomes on CINV Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian ChemoTherapy InduCed Emesis burden of illness Study. Cancer Res Treat 2016;48:1420-1428.
14. Lee SJ, Kang BW, Chae YS, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer. Ann Surg Oncol 2016;23(3):894-9.
15. Kang BW, Seo AN, Yoon S, Bae HI, Jeon SW, Kwon OK, Chung HY, Yu W, Kim JG. Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. Ann Oncol 2016;27:494-501.
16. Yoon S, Kim JG, Seo AN, Park SY, Kim HJ, Park JS, Choi GS, Jeong JY, Jun do Y, Yoon GS, Kang BW. Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer. Oncology. 2015;89(6):351-359.
17. Kang BW, Kim JG, Park H, Park BE, Jeon SW, Bae HI, Kwon OK, Chung HY, Yu W. Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer. Chonnam Med J 2015;51:81-85.
18. Lee M, Son M, Ryu E, Shin YS, Kim JG, Kang BW, Cho H, Kang H. Quercetin-induced apoptosis prevents EBV infection. Oncotarget 2015;6:12603-126024.
19. Kim JY, Ryoo HM, Bae SH, Kang BW, Chae YS, Yoon S, Baek JH, Kim MK, Lee KH, Lee SA, Song HS, Kim JG. Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer. Anticancer Res. 2015 Jun;35(6):3531-6.
20. Kang S, Chae YS, Lee SJ, Kang BW, Kim JG, Kim WW, Jung JH, Park HY, Jeong JH, Jeong JY, Park JY. Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer. Anticancer Res 2015;35:2775-2782.
21. Lee SJ, Kang BW, Chae YS, Cho SH, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol 2015:76:29-34.
22. Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, Han HS, Chung IJ, Song EK, Lee KH, Kang SY, Kang YK. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 2015;51:482-488.
23. Kang BW, Kim JG, Lee SJ, Chae YS, Jeong JY, Yoon GS, Park SY, Kim HJ, Park JS, Choi GS, Jeong JY. Expression of Aquaporin-1, Aquaporin-3, and Aquaporin-5 Correlates with Nodal Metastasis in Colon Cancer. Oncology 2015;88:369-376.
24. Kang BW, Jeon HS, Chae YS, Lee SJ, Park JY, Choi JE, Park JS, Choi GS, Kim JG. Association between GWAS-Identified Genetic Variations and Disease Prognosis for Patients with Colorectal Cancer. PLoS One 2015;23:10:e0119649.
25. Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. Korean J Inter Med 2014;6:785-792.
26. Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, Dalen J, Jung H, Liu YP, Burke TA, Keefe DM. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer 2015;23:263-272.
27. Lee SJ, Seo JW, Chae YS, Kim JG, Kang BW, Kim WW, Jung JH, Park HY, Jeong JY, Park JY. Genetic polymorphism of miR-196a as a prognostic biomarker for early breast cancer. Anticancer Res 2014;34:2943-9.
28. Kim JG, Chae YS, Lee SJ, Kang BW, Park JY, Lee EJ, Jeon HS, Park JS, Choi GS. Genetic variation in microRNA-binding site and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 2015;141:35-41.
29. Lee SJ, Kang BW, Chae YS, Kim HJ, Park SY, Choi GS, Jeon HS, Lee WK, Kim JG. Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with cholorectal cancer. Ann Surg Oncol 2014;4:634-639.
30. Kang BW, Kim JG, Kwon OK, Chung HY, Yu W. Non-platinum-based chemotherapy for treatment of advanced gastric cancer. 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol 2014;20:5396-5402.
31. Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, Kim WS, Lee JJ, Lee SR, Park KU, Lee HS, Lee WS, Won JH, Park MR, Kwak JY, Kim MK, Kim HJ, Oh SY, Kang HJ, Suh C. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. Blood Res 2014;49:15-21.
32. Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Invest New Drugs 2014;32:561-568.
33. Park SY, Choi GS, Park JS, Kim HJ, Ryuk JP, Yun SH, Kim JG, Kang BW. Laparoscopic cytoreductive surgery and early postoperative intraperitoneal chemotherapy for patients with colorectal cancer peritoneal carcinomatosis: initial results from a single center. Surg Endosc 2014;28:1555-1562.
34. Lee SJ, Chae YS, Kim JG, Kim WW, Jung JH, Park HY, Jeong JY, Park JY, Jung HJ, Kwon TH. AQP5 Expression Predicts Survival in Patients with Early Breast Cancer. Ann Surg Oncol 2014;21:375-383.
35. Lee HY, Kim HK, Lee KH, Kim BS, Song HS, Yang SH, Kim JH, Kim YH, Kim JG, Kim SW, Kim DW, Kim SY, Park HS. A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy. Cancer Res Treat 2014;48:19-28.
36. Lim SM, Chang H, Yoon MJ, Hong YK, Kim H, Chung WY, Park CS, Nam KH, Kang SW, Kim MK, Kim SB, Lee SH, Kim HG, Na II, Kim YS, Choi MY, Kim JG, Park KU, Yun HJ, Kim JH, Cho BC. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 2013;24:3089-3094.
37. Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: A randomized phase II study. Clin Colorectal Cancer 2013;12:239-247.
38. Chae YS, Kim JG, Lee SJ, Kang BW, Lee YJ, Park JY, Jeon HS, Park JS, Choi GS. A miR-146a polymorphism (rs2910164) predict risk of and survival from colorectal cancer. Anticancer Res 2013;33:3233-3239.
39. Kang BW, Moon JH, Chae YS, Lee SJ, Kim JG, Kim YK, Lee JJ, Yang DH, Kim HJ, Kim JY, Do YR, Park KU, Song HS, Kwon KY, Kim MK, Lee KH, Hyun MS, Ryoo HM, Bae SH, Kim H, Sohn SK. Clinical outcome of rituximab-based therapy (RCHOP) in diffuse large B-cell lymphoma patients with bone marrow involvement. Cancer Res Treat 2013;45:112-127.
40. Kim JG, Lee SJ, Chae YS, Kang BW, Lee YJ, Oh SY, Kim MC, Kim KH, Kim SJ. Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer. Oncology 2013;85:78-85
41. Kim JG. Molecular targeted therapy for advanced gastric cancer. Korean J Inter Med 2013;28:149-155.
42. Kang BW, Kim JG, Chae YS, Bae HI, Kwon O, Chung HY, Yu W, Song HS, Kang YN, Ryu SW, Lee KH, Bae YK, Choi JH, Kim SW, Ryoo HM, Cho CH, Chae HD, Park KW, Gu MJ, Bae BJ. Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors. Asia Pac J Clin Oncol 2014;10:e40-45.
43. Lee SJ, Kim JG, Lee SW, Chae YS, Kang BW, Lee YJ, Park JS, Choi GS. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol 2013;71:1201-1207.
44. Chae YS, Kim JG, Kang BW, Lee SJ, Lee YJ, Park JS, Choi GS, Lee WK, Jeon HS. Functional polymorphism in the MicroRNA-367 binding site as a prognostic factor for colonic cancer. Anticancer Res 2013;33:513-519.
45. Chae YS, Kim JG, Kang BW, Lee SJ, Jeon HS, Park JS, Choi GS, Lee WK. PPP1R13L variant associated with prognosis for patients with rectal cancer. J Cancer Res Clin Oncol 2013;139:465-473.
46. Kang BW, Jeong JY, Chae YS, Lee SJ, Lee YJ, Choi JY, Lee IK, Jeon SW, Bae HI, Lee da K, Kwon OK, Chung HY, Yu W, Kim JG. Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 2012;70:735-741.
47. Chae YS, Shin H, Sohn SK, Lee SJ, Moon JH, Kang BW, Kim JG, Yang DH, Lee JJ, Park TI. Absolute lymphocyte count at day +21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. Leuk Lymphoma 2012; 53: 1757-1763.
48. Choi WH, Ryuk J, Kim HJ, Park SY, Park JS, Kim JG, Choi GS. A case of giant rectal villous tumor with severe fluid-electrolyte imbalance treated by laparoscopic low anterior resection. J Korean Surg Soc 2012; 82: 325-329.
49. Kwon O, Chung HY, Yu W, Bae HI, Chae YS, Kim JG, Kang BW, Lee WK. Clinical significance of insulin-like growth factor gene polymorphisms with survival in patients with gastrointestinal stromal tumors. J Korean Surg Soc 2012; 82: 288-295.
50. Kang BW, Kim JG, Chae YS, Lee YJ, Moon JH, Sohn SK, Jung MK, Jeon SW, Jang YJ, Lee YH, Kwon O, Chung HY, Yu W. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs 2012; 30: 1671-1675.
51. Choi JY, Kim JG, Lee YJ, Chae YS, Sohn SK, Moon JH, Kang BW, Jung MK, Jeon SW, Park JS, Choi GS. Prognostic impact of polymorphisms in the CASPASE gene on survival of patients with colorectal cancer. Cancer Res Treat 2012;44:32-36.
52. Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK. Imatinib efficacy by tumor genotype in Korean patients with adnvanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta Oncol 2012; 51: 528-536.
53. Moon JH, Lee SJ, Lee YJ, Kang BW, Chae YS, Kim JG, Suh JS, Sohn SK. Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast. Ann Hematol 2012;91:367-373.
54. Lee SJ, Kang BW, Moon JH, Chae YS, Kim JG, Jung JS, Cho GJ, Jo DY, Kim YK, Kim HJ, Ryoo HM, Eom HS, Le SM, Joo YD, Won JH, Park MR, Kim MK, Hyun MS, Sohn SK. Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia. Acta Haematol 2012; 127: 81-89.
55. Kang BW, Kim JG, Lee SJ, Chae YS, Moon JH, Sohn SK, Jeon SW, Jung MK, Lim KH, Jang YS, Park JS, Jeon SH, Choi GS. Clinical significance of microsattelite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine. Med Oncol 2011; 28: S214-S218.
56. Chae YS, Lee SJ, Moon JH, Kang BW, Kim JG, Sohn SK, Jung JH, Park HY, Park JY, Kim HJ, Lee SW. VARS2 V552V variant as prognostic marker in patients with early breast cancer. Med Oncol 2011; 28: 1273-1280.
57. Kim YJ, Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kang BW, Park JY, Park JS, Choi GS. No association of the eNOS gene polymorphisms with survival in patients with colorectal cancer. Med Oncol 2011; 28: 1075-1079.
58. Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kang BW, Park JS, Park JY, Choi GS. No association of the hypoxia-inducible factor-1α gene polymorphisms with survival in patients with colorectal cancer. Med Oncol 2011; 28: 1075-1079.
59. Chae YS, Kim JG, Jung HJ, Yang JD, Jung JH, Aiyar SE, Kim S, Park H. Anticancer effect of (E)-2-hydroxy-3',4,5'-trimethoxystilbene on breast cancer cells by mitochondrial depolarization. Cancer Chemother Pharmacol 2011; 68: 349-58.
60. Kim JG, Chae YS, Sohn SK, Kang BW, Moon JH, Lee SJ, Jeon SW, Park JS, Park JY, Choi GS. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer. Oncology 2011; 79: 278-282.
61. Cho YY, Kim JG, Chae YS, Sohn SK, Kang BW, Moon JH, Jeon SW, Park JS, Park JY, Choi GS. No association of insulin-like growth factor gene polymorphisms with survival in patients with colorectal cancer. Cancer Res Treat 2011; 43: 189-194.
62. Chae YS, Kim JG, Sohn SK, Lee SJ, Kang BW, Moon JH, Park JY, Jeon SW, Bae HI, Choi GS, Jun SH. RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection. J Cancer Res Clin Oncol 2011;137:705-713.
63. Kim JY, Do YR, Park KU, Kim JG, Chae YS, Kim MK, Lee KH, Ryoo HM, Bae SH, Baek JH, Song HS. Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2011; 67: 527-532.
64. Moon JH, Kim SN, Kang BW, Chae YS, Kim JG, Ahn JS, Kim YK, Yang DH, Lee JJ, Kim HJ, Choi YJ, Shin HJ, Chung JS, Cho GJ, Sohn SK. Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset. Bone Marrow Transplant. 2010 Oct;45(10):1540-5.
65. Kim JG, Chung HY, Yu W. Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol 2010;15:287-294.
66. Kang BW, Moon JH, Chae YS, Kim JG, Jung JS, Cho GJ, Jo DY, Kim YK, Kim HJ, Ryoo HM, Eom HS, Lee SM, Joo YD, Won JH, Park MR, Kim MK, Hyun MS, Sohn SK. Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors. Ann Hematol 2010;89:813-20.
67. Park JH, Kim NS, Park JY, Chae YS, Kim JG, Sohn SK, Moon JH, Kang BW, Ryoo HM, Bae SH, Choi GS, Jun SH. MGMT 535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy. J Cancer Res Clin Oncol 2010;136:1135-1142.
68. Kang BW, Moon JH, Chae YS, Kim JG, Kim SN, Sohn SK. Pre-Emptive Treatment with Nilotinib after Second Allogeneic Transplantation in a Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patient with High Risk of Relapse. Acta Haematol 2010;123:242-247.
69. Moon JH, Kim SN, Kang BW, Chae YS, Kim JG, Baek JH, Park JH, Song MK, Chung JS, Won JH, Lee SM, Joo YD, Kim YK, Kim HJ, Jo DY, Sohn SK. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol 2010;89:681-689.
70. Lee HC, Kim JG, Chae YS, Sohn SK, Kang BW, Moon JH, Jeon SW, Lee MH, Lim KH, Park JY, Choi GS, Jun SH. Prognostic impact of microRNA-related gene polymorphisms on survival of patients with colorectal cancer. J Cancer Res Clin Oncol 2010;136:1073-1078.
71. Jung JH, Chae YS, Moon JH, Kang BW, Kim JG, Sohn SK, Park JY, Lee MH, Park HY. TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol 2010;136:685-94.
72. Kim JG, Chae YS, Sohn SK, Moon JH, Kang BW, Park JY, Jeon SW, Lee MH, Lim KH, Choi GS, Jun SH. IVS10+A>G polymorphism in hMSH2 gene associated with prognosis for patients with colorectal cancer. Ann Oncol 2010;21:525-529.
73. Chae YS, Kim JG, Sohn SK, Moon JH, Kim SN, Lee SJ, Park TI, Lee MH. Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. Cancer Chemother Pharmacol 2010;65:571-577.
74. Oh SY, Kim WS, Kim SJ, Kim JS, Kim SH, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Kim JG, Yang DH, Kang HJ, Choi CW, Park J, Choi YJ, Kim HJ, Kwon JH, Suh C, Kim HJ. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol 2009;84(12):826-9.
75. Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, Hwang YJ, Sohn SK. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. In J Hematol 2009;90:383-387.
76. Kim SN, Moon JH, Kim JG, Chae YS, Cho YY, Lee SJ, Kim YJ, Lee YJ, Suh JS, Lee KS, Sohn SK. Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation. J Clin Apher 2009;24(5):173-9.
77. Kim JG, Chae YS, Sohn SK, Moon JH, Ryoo HM, Bae SH, Kum Y, Jeon SW, Lim KH, Kang BM, Park IJ, Choi GS, Jun SH. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol 2009;64:953-960.
78. Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Kang BW, Kim GC, Lee MH, Jeon SW, Chung HY, Yu W. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in patients with gastric cancer. Jpn J Clin Oncol 2009;39:497-501.
79. Moon JH, Lee SJ, Kim JG, Chae YS, Kim SN, Kang BW, Suh JS, Lee KS, Sohn SK. Clinical significance of autoantibody expression in allogeneic stem-cell recipients. Transplantation 2009;88:242-50.
80. Chae YS, Kim JG, Moon JH, Kim SN, Lee SJ, Kim YJ, Sohn SK. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant. 2009;44:35-41.
81. Lee SR, Yang DH, Ahn JS, Kim YK, Lee JJ, Choi YJ, Shin HJ, Chung JS, Cho YY, Chae YS, Kim JG, Sohn SK, Kim HJ. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia. J Korean Med Sci. 2009;24:498-503.
82. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Lee WS, Sohn CH, Jung JS, Kim GC, Chung HY, Yu W. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 2009;64:355-60.
83. Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH. Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy. Clin Cancer Res 2009;15:2107-2115.
84. Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Bae HI, Chung HY, Yu W. No association of of Vascular Endothelial Growth Factor-A (VEGF-A) and VEGF-C Expression with Survival in Patients with Gastric Cancer. Cancer Res Treat 2009;41(4):218-223.
85. Lee SJ, Ahn BM, Kim JG, Sohn SK, Chae YS, Moon JH, Lee EB, Kim JC, Park IK, Jeon SW. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci 2009;24:120-125.
86. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008;99:584-590.
87. Shin HJ, Chung JS, Lee JJ, Sohn SK, Choi YJ, Kim YK, Yang DH, Kim HJ, Kim JG, Joo YD, Lee WS, Sohn CH, Lee EY, Cho GJ. Treatment Outcomes with CHOP Chemotherapy in Adult Patients with Hemophagocytic Lymphohistiocytosis. J Korean Med Sci 2008;23:439-44.
88. Chae YS, Kim JG, Sohn SK, Cho YY, Ahn BM, Moon JH, Jeon SW, Park JY, Lee IT, Choi GS, Jun SH. Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer. J Korean Med Sci 2008;23:421-7.
89. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Yang DH, Lee JJ, Kim YK, Kim HJ, Shin HJ, Chung JS, Cho GJ. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. Am J Hematol 2008;83:649-653.
90. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Ryoo HM, Bae SH, Park KU, Lee WS, Baek JH, Chung HY, Yu W. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. British Journal of Cancer 2008:98:542-546.
91. Kim MK, Lee JL, Hyun MS, Do YR, Song HS, Kim JG, Bae SH, Ryoo HM, Park KU, Lee KH. Palliative chemotherapy preferences and factors that influence patient choice in incurable advanced cancer. Jpn J Clin Oncol 2008;38:64-70.
92. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2008;61:301-307.
93. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS, Jun SH. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008;14:62-66.
94. Lee JY, Lee WS, Jung MK, Jeon SW, Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH, Kim JG, Sohn SK. Acute myeloid leukemia presenting as obstructive jaundice caused by granulcytic sarcoma. Gut Liver 2007;1:182-185.
95. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007;40:919-924
96. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, Chung JS, Cho GJ, Yang DH, Lee JJ, Kim YK, Kim HJ. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant. 2007;40:541-547
97. Sohn SK, Moon JH, Cho YY, Chae YS, Kim JG, Lee KS, Hong SP, Kim SO. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance. Leuk Lymphoma. 2007;48:1659-61.
98. Chae YS, Kim JG, Sohn SK, Cho YY, Moon JH, Bae HI, Park JY, Lee MH, Lee HC, Chung HY, Yu W. Investigation of Vascular Endothelial Growth Factor Gene Polymorphisms and Its Association with Clinicopathologic Characteristics in Gastric Cancer. Oncology. 2007;71:266-272.
99. Moon JH, Kim JG, Sohn SK, Baek JH, Cho YY, Chae YS, Ahn BM, Kim SN, Lee SJ, Lee IT, Choi GS, Jun SH. Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer. J Korean Med Sci. 2007;22:400-404
100. Park BB, Kim JG, Sohn SK, Kang HJ, Lee SS, Eom HS, Kwon HC, Oh SY, Kang JH, Oh SJ, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, Kim WS. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol. 2007;82:840-845.
101. Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol 2007;137:329-336.
102. Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, Kim HJ, Shin HJ, Chung JS, Cho GJ, Lee WS, Joo YD, Sohn CH, Oh S. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60:129-134
103. Kim JG, Sohn SK, Chae YS, Cho YY, Bae HI, Yan G, Park JY, Lee MH, Chung HY, Yu W. Vascular endothelial growth factor (VEGF) gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007;18:1030-1036
104. Kim JG, Sohn SK, Song SK, Kwon KY, Do YR, Lee KH, Hyun MS, Ryoo HM, Bae SH, Park KU, Baek JH, Lee WS, Chung JS, Cho GJ, Sohn CH, Jang JS, Chung HY, Yu WS. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2007;60:863-869.
105. Baek JH, Sohn SK, Kim DH, Kim JG, Yang DH, Kim YK, Lee JJ, Kim HJ. Pilot Remission Induction Therapy with Idarubicin, plus an Intensified Dose of Ara-C and Priming with Granulocyte Colony-Stimulating Factor for Acute Myeloid Leukemia. Acta Haematol 2007;117:109-114.
106. Jung JT, Kim DH, Kwak EK, Kim JG, Park TI, Sohn SK, Do YR, Kwon KY, Song HS, Park EH, Lee KB. Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. Ann Hematol 2006;85:575-581.
107. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK. FcGRIIIa gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-2725.
108. Baek JH, Kim JG, Jeon SB, Chae YS, Kim DH, Sohn SK, Lee KB, Choi YJ, Shin HJ, Chung JS, Cho GJ, Jung HY, Yu W. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer. 2006;94:1407-1411.
109. Sohn SK, Kim DH, Baek JH, Kim JG, Lee KB, Lee KH, Choi SJ, Lee JH, Shin IH. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2006;37:699-708.
110. Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK: Lymphoma Study Division of the Korean Cancer Study Group. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol. 2006;85:257-262.
111. Sohn SK, Kim JG, Kim DH. Tailored strategy for AML patients receiving allogeneic peripheral blood stem cell transplantation. J Clin Apher 2006;21:207-213.
112. Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, Lee KB. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer. 2006;118:2195-2201.
113. Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB, Lee JJ, Chung IJ, Kim HJ, Yang DH, Lee WS, Joo YD, Sohn CH. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol. 2006;58:31-39.
114.
Kim DH, Sohn SK, Baek JH, Kim JG, Won DI, Suh
JS, Lee KB. Clinical Significance of Platelet Count at day +60 After Allogeneic
Peripheral Blood Stem Cell Transplantation. J Korean Med Sci. 2006;
115. Kim DH, Jung HD, Kwack DH, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB, Shin IH. Predicting outcomes of HLA-identical allogeneic stem cell transplants from variable number of tandem repeat disparity between donors and recipients. Haematologica. 2006;91:71-77.
116. Kim DH, Won DI, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB. Survival Benefit of Asymptomatic Cytomegalovirus Reactivation after HLA-Identical Allogeneic Peripheral Blood Stem Cell Transplantation. Transplantation. 2006;81:101-108.
117. Kim DH, Lee NY, Baek JH, Kim JG, Sohn SK, Suh JS, Lee KS, Lee KB. Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia. Leuk Lymphoma. 2006;47:461-467.
118. Choe YS, Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Do YR, Kwon KY, Song HS, Lee MH, Park TI. c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas. Leuk Lymphoma. 2006; 47:267-270.
119. Kim DH, Sohn SK, Jeon SB, Baek JH, Kim JG, Lee NY, Suh JS, Lee KB, Shin IH. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant 2006; 37:101-108.
120. Kim MK, Lee KH, Hyun MS, Do YR, Song HS, Lee WS, Park KU, Baek JH, Kim JG. A multicenter, phase II clinical trial of padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat 2005;37:349-353.
121. Kim JG, Sohn SK, Baek JH, Kim DH, Bae NY, Kim SY, Lee KB. Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation. Transplant Proc. 2005;37:4488-4491.
122. Baek JH, Kim JG, Sohn SK, Kim DH, Lee KB, Song HS, Kwon KY, Do YR, Ryoo HM, Bae SH, Park KU, Kim MK, Lee KH, Hyun MS, Chung HY, Yu W. Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study. J Korean Med Sci. 2005; 20:966-970.
123. Seo KW, Kim DH, Sohn SK, Lee NY, Chang HH, Kim SW, Jeon SB, Baek JH, Kim JG, Suh JS, Lee KB. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36:1089-1095.
124. Kim JG, Sohn SK, Kim DH, Baek JH, Jeon SB, Chae YS, Lee KB, Park JS, Sohn JH, Kim JC, Park IK. Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2005; 93:1117-1121.
125. Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB. Phase II Trial of Amsacrine Plus Intermediate-dose Ara-C (IDAC) with or without Etoposide as Salvage Therapy for Refractory or Relapsed Acute Leukemia. Jpn J Clin Oncol 2005; 35:612-616.
126. Kim DH, Sohn SK, Lee NY, Baek JH, Kim JG, Won DI, Suh JS, Lee KB, Shin IH. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Haematol 2005; 75:299-308.
127. Kim DH, Lee NY, Sung WJ, Baek JH, Kim JG, Sohn SK, Suh JS, Lee KS, Lee KB. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes. Acta Haematol 2005; 114:78-83.
128. Kim JG, Sohn SK, Kim DH, Baek JH, Sung WJ, Park JY, Kim TB, Jung HY, Yu W, Lee KB. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68: 190-195.
129. Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, Lee KB. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leukemia lymphoma 2005; 46: 885-891.
130. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB, Sohn SK, Kim JG, Kim DH, Seol M, Lee YS, Lee JH. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90:939-48.
131. Kim DH, Sohn SK, Baek JH, Kim JG, Lee JW, Min WS, Kim DW, Choi SJ, Lee JH, Lee KH, Lee MH, Lee JJ, Kim HJ, Kim CC, Lee KB. Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen. Acta Haematol 2005;113(4):220-7.
132. Kim DH, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB, Shin IH. IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course During Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation. Transplantation 2005; 79:1615-1622.
133. Baek JH, Sohn SK, Kim DH, Kim JG, Lee HW, Park SP, Lee KB. Wernicke's encephalopathy after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 35: 829-830.
134. Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Min WS, Kim CC, Lee MH, Lee JJ, Chung IJ, Kim HJ, Lee JW. Impact of ABO incompatibility on outcomes after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 489-495.
135. Kim DH, Lee NY, Kim JG, Sohn SK, Won DI, Suh JS, Lee GS, Chae SC, Lee KB. Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia. Leukemia lymphoma 2005; 46: 63-70.
136. Kim DH, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH, Suh JS, Lee KS, Lee KB. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. Ann Hematol 2005; 84: 25-32.
137. Kim JG, Sohn SK, Kim DH, Baek JH, Park TI, Lee KB. Phase II study of cyclophosphamide, epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin’s lymphoma. J Kerean Med Sci 2004; 19: 765-771.
138. Kim DH, Bae NY, Sung WJ, Kim JG, Kim SW, Baek JH, Chang HH, Sohn SK, Lee KB. Hickman catheter site infections after allogeneic stem cell transplantation: a single-center experience. Transplant Proc. 2004; 36: 1569-1573.
139. Sohn SK, Kim JG, Kim DH, Baek JH, Lee KB. Diverse clinical applications using advantage of allogeneic peripheral stem cell transplantation. Int J Hematol 2004; 79: 457-461.
140. Sohn SK, Kim DH, Kim JG, Lee NY, Suh JS, Lee KS, Lee KB. Outcome of allogeneic peripheral blood stem cell transplantation using mached sibling donors in patients with high-risk hematological diseases. Eur J of Haematology 2004; 72; 430-436.
141. Sohn SK, Kim DH, Kim JG, Lee NY, Suh JS, Lee KS, Lee KB. Transplantation outcome in allogeneic PBSCT patients according to new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. Bone Marrow Transplant 2004; 34: 63-68.
142. Kim DH, Kim JG, Sohn SK, Sung WJ, Suh JS, Lee KS, Lee KB. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. British J of Haematology 2004; 125: 217-224.
143. Kim DH, Sohn SK, Lee NY, Sung WJ, Kim JG, Suh JS, Lee KS, Lee KB. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: DLI and previous history of early CMV infection. Bone Marrow Transplant 2004; 34: 21-27.
144. Kim DH, Sohn SK, Kim JG, Suh JS, Lee KS, Lee KB. Clinical impact of hyperacute graft-versus-host disease on results of allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 1025-1030.
145. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, Lee KB. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant. Bone Marrow Transplant 2004;33:231-236.
146. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, Lee KB. Different efficacy of Mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J of Haematology 2004; 73: 56-61.
147. Sohn SK, Kim JG, Sung WJ, Kim DH, Suh JS, Lee KS, Lee KB. Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization. J of Clin Apheresis 2003;18:186-189.
148. Sohn SK, Kim JG, Kim DH, Lee NY, Suh JS, Lee KB. Cardiac morbidity in advanced chronic myelogenous leukemia patients treated by successive allogeneic stem cell transplantation with busulfan/cyclophosphamide conditioning after STI-571 administration. British J of Hematology 2003;121:469-472.
149. Sohn SK, Kim JG, Chae YS, Kim DH, Lee NY, Suh JS, Lee KB. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with Fenwal CS 3000 Plus from normal healthy donors: Predictors of CD34+ cell yield and collection efficiency. J of Clin Apheresis 2003;18:10-15..
150. Sohn SK, Jung JT, Suh KW, Chae YS, Kim JG, Park TI, Shin DG, Sohn KR, Lee KB. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J of Hematology 2003;73:101-107.
151. Sohn SK, Kim JG, Kim DH, Lee NY, Suh JS, Lee KB. Impact of transplanted CD 34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;31:967-972.
152. Sohn SK, Kim JG, Seo KW, Chae YS, Jung JT, Suh JS, Lee KB. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;30:81-86.
153. Sohn SK, Jung JT, Suh KW, Lee NY, Seo KW, Chae YS, Park SW, Kim JG, Suh JS, Lee KB. Prophylactic growth factor-primed donor lymphocyte infusion using cells additionally reserved at the time of transplant after allogeneic peripheral blood stem cell transplantation in high-risk hematological malignancies. Cancer 2002; 94: 18-24.